447 related articles for article (PubMed ID: 17134554)
21. The VHL tumor suppressor and HIF: insights from genetic studies in mice.
Kapitsinou PP; Haase VH
Cell Death Differ; 2008 Apr; 15(4):650-9. PubMed ID: 18219317
[TBL] [Abstract][Full Text] [Related]
22. The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease.
Haase VH
Kidney Int; 2006 Apr; 69(8):1302-7. PubMed ID: 16531988
[TBL] [Abstract][Full Text] [Related]
23. Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism.
Leisz S; Schulz K; Erb S; Oefner P; Dettmer K; Mougiakakos D; Wang E; Marincola FM; Stehle F; Seliger B
Oncotarget; 2015 May; 6(13):11395-406. PubMed ID: 25890500
[TBL] [Abstract][Full Text] [Related]
24. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.
Carroll VA; Ashcroft M
Cancer Res; 2006 Jun; 66(12):6264-70. PubMed ID: 16778202
[TBL] [Abstract][Full Text] [Related]
25. VHL gene alterations in Italian patients with isolated renal cell carcinomas.
Muscarella LA; D'Agruma L; la Torre A; Gigante M; Coco M; Parrella P; Battaglia M; Carrieri G; Carella M; Zelante L; Fazio VM; Gesualdo L; Ranieri E
Int J Biol Markers; 2013 Jun; 28(2):208-15. PubMed ID: 23558940
[TBL] [Abstract][Full Text] [Related]
26. Collagen matrix assembly is driven by the interaction of von Hippel-Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2.
Kurban G; Duplan E; Ramlal N; Hudon V; Sado Y; Ninomiya Y; Pause A
Oncogene; 2008 Feb; 27(7):1004-12. PubMed ID: 17700531
[TBL] [Abstract][Full Text] [Related]
27. Von hippel-lindau: a tumor suppressor links microtubules to ciliogenesis and cancer development.
Kuehn EW; Walz G; Benzing T
Cancer Res; 2007 May; 67(10):4537-40. PubMed ID: 17510376
[TBL] [Abstract][Full Text] [Related]
28. [Von-Hippel-Lindau (VHL) protein function by initiation and progression of renal cancer].
Moch H
Pathologe; 2008 Nov; 29 Suppl 2():149-52. PubMed ID: 18751708
[TBL] [Abstract][Full Text] [Related]
29. Clinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma.
Sorrell AD; Lee S; Stolle C; Ellenhorn J; Grix A; Kaelin WG; Weitzel JN
Clin Genet; 2011 Jun; 79(6):539-45. PubMed ID: 20560986
[TBL] [Abstract][Full Text] [Related]
30. Consequences of VHL Loss on Global DNA Methylome.
Robinson CM; Lefebvre F; Poon BP; Bousard A; Fan X; Lathrop M; Tost J; Kim WY; Riazalhosseini Y; Ohh M
Sci Rep; 2018 Feb; 8(1):3313. PubMed ID: 29463811
[TBL] [Abstract][Full Text] [Related]
31. Mutational analysis of the von hippel lindau gene in clear cell renal carcinomas from tuberous sclerosis complex patients.
Duffy K; Al-Saleem T; Karbowniczek M; Ewalt D; Prowse AH; Henske EP
Mod Pathol; 2002 Mar; 15(3):205-10. PubMed ID: 11904337
[TBL] [Abstract][Full Text] [Related]
32. Structural bioinformatics mutation analysis reveals genotype-phenotype correlations in von Hippel-Lindau disease and suggests molecular mechanisms of tumorigenesis.
Forman JR; Worth CL; Bickerton GR; Eisen TG; Blundell TL
Proteins; 2009 Oct; 77(1):84-96. PubMed ID: 19408298
[TBL] [Abstract][Full Text] [Related]
33. Primary cilium formation requires von hippel-lindau gene function in renal-derived cells.
Lutz MS; Burk RD
Cancer Res; 2006 Jul; 66(14):6903-7. PubMed ID: 16849532
[TBL] [Abstract][Full Text] [Related]
34. Arginine refolds, stabilizes, and restores function of mutant pVHL proteins in animal model of the VHL cancer syndrome.
Shmueli MD; Levy-Kanfo L; Haj E; Schoenfeld AR; Gazit E; Segal D
Oncogene; 2019 Feb; 38(7):1038-1049. PubMed ID: 30194449
[TBL] [Abstract][Full Text] [Related]
35. Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation.
He Z; Liu S; Guo M; Mao J; Hughson MD
Cancer Genet Cytogenet; 2004 Jul; 152(2):89-94. PubMed ID: 15262424
[TBL] [Abstract][Full Text] [Related]
36. Differences in Tumor VHL Mutation and Hypoxia-inducible Factor 2α Expression Between African American and White Patients with Clear Cell Renal Cell Carcinoma.
Callahan CL; Moore L; Lenz P; Linehan WM; Nickerson ML; Rothman N; Purdue MP
Eur Urol; 2019 May; 75(5):882-884. PubMed ID: 30655088
[No Abstract] [Full Text] [Related]
37. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
38. Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins.
Rohan SM; Xiao Y; Liang Y; Dudas ME; Al-Ahmadie HA; Fine SW; Gopalan A; Reuter VE; Rosenblum MK; Russo P; Tickoo SK
Mod Pathol; 2011 Sep; 24(9):1207-20. PubMed ID: 21602815
[TBL] [Abstract][Full Text] [Related]
39. Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis.
Kurban G; Hudon V; Duplan E; Ohh M; Pause A
Cancer Res; 2006 Feb; 66(3):1313-9. PubMed ID: 16452184
[TBL] [Abstract][Full Text] [Related]
40. Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma.
Luu VD; Boysen G; Struckmann K; Casagrande S; von Teichman A; Wild PJ; Sulser T; Schraml P; Moch H
Clin Cancer Res; 2009 May; 15(10):3297-304. PubMed ID: 19401348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
